结外鼻型NK/T细胞淋巴瘤的内科治疗  

Internal medical management of extranodal nasal type NK/T cell lymphoma

作　　者：王静静[1] 董梅[1] 

机构地区：[1]北京协和医学院中国医学科学院肿瘤医院肿瘤内科,100021

出　　处：《国际肿瘤学杂志》2015年第1期71-73,共3页Journal of International Oncology

基　　金：中国医学科学院肿瘤医院重点科研课题（LC2010A05）

摘　　要：结外鼻型自然杀伤（NK）/T细胞淋巴瘤是一种高度侵袭性非霍奇金淋巴瘤,因发病率低,缺乏大样本前瞻性随机对照研究,仍未确定标准一线化疗方案.因多药耐药基因1高表达,对蒽环类药物为主的常规化疗抗拒.近年来出现一些有效率较高的方案,含左旋门冬酰胺酶或吉西他滨的方案近期有效率高,可作为首选方案,而靶向治疗、免疫调节治疗和造血干细胞移植仍在探索之中.Extranodal nasal type NK/T cell lymphoma （ENKTL） is a highly aggressive non-Hodgkin lymphoma.Due to its low occurrence even in prevalent areas,there has been no large sample randomized controlled clinical trials.Therefore,no standard therapeutic strategy is currently identified in this disease.Tumor cells are insensitive to conventional anthracyclines-containing chemotherapy because of high expression of multi-drug resistant gene 1.Regimens that incorporate the use of L-asparaginase or gemcitabine result in substantial improvements in overall response rate and are promising treatment for ENKTL.Targeted therapy,immunomodulatory therapy and hematopoietic stem cell transplantation are still under research.

关 键 词：淋巴瘤 结外NK/T细胞 药物疗法 造血干细胞移植 

分 类 号：R733.1[医药卫生—肿瘤]